BLAINJECTIONINJECTABLEPriority Review
Approved
Nov 2011
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
36
Data completeness
7/8 — Comprehensive
Priority Review
EYLEA (aflibercept) by Regeneron is vascular endothelial growth factor inhibitors [moa]. Approved for vascular endothelial growth factor inhibitor [epc]. First approved in 2011.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EYLEA (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor administered by intravitreal injection for the treatment of retinal diseases, including age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. It functions as a fusion protein that acts as a soluble decoy receptor, binding and neutralizing VEGF and placental growth factor (PlGF) to inhibit abnormal blood vessel growth and vascular leakage. Approved by the FDA in November 2011, EYLEA is a first-in-class therapy that has become a standard of care for wet AMD and other retinal vascular disorders.
$0.1BPart D
Mechanism of Action
Vascular Endothelial Growth Factor Inhibitors
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (36)
Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial
Started Dec 2026
50 enrolled
Polypoidal Choroidal VasculopathyPolypoidal Choroidal Vasculopathy (PCV)
Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema
Started Apr 2026
256 enrolled
Diabetic Macular Edema
A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration
Started Mar 2026
356 enrolled
Neovascular Age-Related Macular Degeneration (nAMD)
A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)
Started Jan 2026
174 enrolled
Polypoidal Choroidal Vasculopathy (PCV)Neovascular Age Related Macular Degeneration (AMD)
High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)
Started Aug 2025
180 enrolled
Wet Age-related Macular Degeneration (wAMD)
Worked on EYLEA at Regeneron? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.